Kantonsspital St.Gallen


Christian Rothermundt

Aeppli S, Engeler D S, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. Swiss Med Wkly 2022; 152:w30175.
Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bührer E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild S I, Seifert B, Templeton A J, Terbuch A, Ufen M P, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022; 40:16-18.
Fankhauser C D, Grogg J B, Rothermundt C, Clarke N W. Treatment and follow-up of rare testis tumours. J Cancer Res Clin Oncol 2022; 148:667-671.
Aeppli S, Schmaus M, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B I, Schmidinger M, Sternberg C N, Rothermundt C, Putora P M. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open 2021; 6:100030.
Fankhauser C D, Christiansen A J, Rothermundt C, Cathomas R, Wettstein M S, Grossmann N C, Grogg J B, Templeton A J, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 2021;.
Beyer J, Berthold D, Bode P K, Cathomas R, Fankhauser C D, Fischer S, Gillessen S, Gross T, Hermanns T, Honecker F, Lorch A, Omlin A, Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M, Stenner F, Bührer E. Swiss germ-cell cancer consensus recommendations. Swiss Med Wkly 2021; 151:.
Van Treeck B J, Thangaiah J J, Torres-Mora J, Stevens T M, Rothermundt C, Fassan M, Loupakis F, Diebold J, Hornick J L, Halling K C, Folpe A L. NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Mod Pathol 2021;.
Iseli T, Fischer G, Panje C, Glatzer M, Hundsberger T, Rothermundt C, Schmidt B, Sirén C, Plasswilm L, Putora P M. Insular Decision Criteria in Clinical Practice: Analysis of Decision-Making in Oncology. Oncology 2020; 98:438-444.
Rothermundt C. Perioperative treatment of soft-tissue sarcoma. memo - Magazine of European Medical Oncology 2020;.
Aeppli S, Eboulet E I, Eisen T, Escudier B, Fischer S, Larkin J, Gruenwald V, McDermott D, Oldenburg J, Omlin A, Porta C, Rini B, Schmidinger M, Sternberg C, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open 2020; 5:.
Hench I B, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre R P, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg P V, Bubendorf L, Vlajnic T, Sakk S G F C C R. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers (Basel) 2019; 11:.
Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, Von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clin Genitourin Cancer 2019;.
Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, Feller A, NICER Working Group . Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. Cancer Epidemiol 2019; 63:101596.
Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C, Gillessen S, Engeler D S, Klingbiel D, Schmid H P, Omlin A. Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. Oncol Res Treat 2019; 42:366-374.
Rothermundt C, Thurneisen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S I, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Gillessen S. Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly 2018; 148:w14674.
Rothermundt C, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N F, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Gillessen S. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly 2018; 148:w14640.
Sandmeier N, Rothschild S I, Rothermundt C, Cathomas R, Schardt J, Berthold D, Von Burg P, Müller B, Beyer J, Vogt D R, Stenner F. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. Clin Genitourin Cancer 2018;.
Herrmann C, Vounatsou P, Thuerlimann B, Probst-Hensch N, Rothermundt C, Ess S. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open 2018; 8:e017806.
Panje C, Glatzer M, Von Rappard J, Rothermundt C, Hundsberger T, Zumstein V, Plasswilm L, Putora P M. Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis. BMC Med Res Methodol 2017; 17:123.
Seddon B, Strauss S J, Whelan J, Leahy M, Woll P J, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal G J, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi H M, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017;.
Rothermundt C, Fischer G, Bauer S, Blay J Y, Grünwald V, Italiano A, Kasper B, Kollár A, Lindner L H, Miah A, Sleijfer S, Stacchiotti S, Putora P M. Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. Oncologist 2017;.
Rothermundt C, Seddon B M, Dileo P, Strauss S J, Coleman J, Briggs T W, Haile S R, Whelan J S. Follow-up practices for high-grade extremity Osteosarcoma. BMC Cancer 2016; 16:301.
Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum C U, Von Rohr L, Von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild S I. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. Clin Genitourin Cancer 2016;.
Cathomas R, Crabb S J, Mark M, Winterhalder R, Rothermundt C, Elliott T, Von Burg P, Kenner H, Hayoz S, Vilei S B, Rauch D, Roggero E, Mohaupt M G, Bernhard J, Manetsch G, Gillessen S, Swiss Group For Clinical Cancer Research SAKK . Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate 2016; 76:1519-1527.
Rothermundt C, Von Rappard J, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C N, Putora P M. Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World J Urol 2016;.
Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar C B, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016;.
Joerger M, Van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 2015;.
Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C, Putora P M. Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma-Analysis Using Diagnostic Nodes. Oncologist 2015; 20:1028-35.
Rothermundt C, Hader C, Gillessen S. Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol 2015;.
Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono J S, Shen L, Su Z, Gillessen S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer 2015;.
Schmid S, Omlin A, Blum D, Strasser F, Gillessen S, Rothermundt C. Assessment of Anticancer-Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer - Going beyond PSA and Imaging, a Systematic Literature Review. Ann Oncol 2015;.
Koehle O, Abt D, Rothermundt C, Oehlschlegel C, Brugnolaro C, Schmid H P. Soft tissue sarcomas of the kidney. Rare Tumors 2015; 7:5635.
Desax M, Hundsberger T, Rothermundt C, Omlin A, Gillessen S. Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. Clin Genitourin Cancer 2015; 13:e385-6.
Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol 2015; 4:310-25.
Gillessen S, De Santis M, Rothermundt C. On Nonharming: The Debate Continues in Stage I Testicular Cancer. J Clin Oncol 2015;.
Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N J, Gillessen S. Abiraterone--what is wrong with the adrenal glands?. Clin Genitourin Cancer 2014; 12:e133-7.
Rothermundt C, Hayoz S, Templeton A, Winterhalder R, Strebel R T, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff J H, Cathomas R, Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 2014; 66:468-74.
Schmid S, Gillessen S, Binet I, Brändle M, Engeler D S, Greiner J, Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stöckli S, Sulz M, Vanleyen K, Weber J, Rothermundt C, Hundsberger T. Management of von Hippel-Lindau Disease: An Interdisciplinary Review. Oncol Res Treat 2014; 37:761-771.
Rothermundt C, Whelan J S, Dileo P, Strauss S J, Coleman J, Briggs T W, Haile S, Seddon B M. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer 2014; 110:2420-6.
Rothermundt C, On Behalf Of All The Authors . Reply from Authors re: Robert J. Hamilton. Metformin for Castrate-resistant Prostate Cancer: Learning More About an Old Dog's New Tricks. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.013: The Stage Is Set for Metformin. Eur Urol 2014;.
Cathomas R, Rothermundt C, Bode B, Fuchs B, Von Moos R, Schwitter M. RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?. Oncology 2014; 88:257-260.
Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. Case Rep Oncol 2013; 6:316-9.
Rothermundt C, Gillessen S. Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor. J Clin Oncol 2013; 31:e57-8.
Rothermundt C, Gillessen S. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol 2013; 31:e57-8.
Dusemund F, Schneider T, Zeisel C, Rothermundt C, Kluckert T, Schmid S, Brutsche M. Endobronchial ultrasound-guided transbronchial needle aspiration of an intravascular sarcoma metastasis. Respiration 2013; 86:430-432.
Templeton A, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild P J, Rüschoff J H, Thalmann G, Dietrich P Y, Aebersold R, Klingbiel D, Gillessen S, Swiss Group For Clinical Cancer Research (SAKK) . Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
Keller S, Putora P, Rothermundt C. Interdiziplinäre Therapie der Extremitäten Weichteil-Sarkome. info@Onkologie 2013; 2:14-17.
Schmid S, Oehlschlegel C, Nagel W, Zeisel C, Müller J, Rothermundt C. Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications. Case Rep Oncol 2013; 6:331-8.
Stenner F, Chastonay R, Liewen H, Haile S R, Cathomas R, Rothermundt C, Siciliano R D, Stoll S, Knuth A, Buchler T, Porta C, Renner C, Samaras P. A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. Oncology 2012; 82:333-340.
Rothermundt C, Putora P M. DESO St. Gallen, 2012: die Therapie des metastasierten Weichteilsarkoms im Erwachsenenalter. Leading Opinions Hämatologie & Onkologie 2012; 2012:1-5.
Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher D C, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold D R, Pless M, Schiess R, Von Moos R, Gillessen S, Swiss Group For Clinical Cancer Research SAKK . Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
Cerny T, Rothermundt C, Putora P M. Palliative Systemtherapie des metastasierten Weichteil-Sarkoms. info@onkologie 2012; 2012:6-9.
Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2012; 23:632-9.
Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, Michelagnoli M, Seddon B, Strauss S. Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas. Clin Sarcoma Res 2012; 2:12.
Keller S, Putora P M, Rothermundt C. Interdisziplinäre Therapie der Extremitäten-Weichteil-Sarkome. info@onkologie 2012; 2012:10-13.
Rothermundt C. Adhärenz und Sicherheit bei oraler Tumortherapie. Swiss Medical Forum 2011; 11:276-278.
Templeton A, Rothermundt C. Metastasiertes Nierenzellkarzinom - Moderne Behandlung bei fortgeschrittenem Stadium. Ars Medici 2010; 15:598-602.
Jungi M, Rothermundt C. Radiation Recall Reaction. Schweizerisches Medizin-Forum 2010; 10:255.
Cathomas R, Helbling D, Stenner F, Rothermundt C, Rentsch C, Shahin O, Seifert H H, Zaugg K, Lorch A, Mayer F, Beyer J, De Santis M, Gillessen S. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med Wkly 2010; 140:356-69.
Omlin A, Kaelin M, Templeton A, Jungi M, Gillessen S, Graf H J, Rothermundt C. Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie. Swiss Medical Forum 2010; 10:483-485.
Ashraf H, Alam N H, Rothermundt C, Brooks A, Bardhan P, Hossain L, Salam M A, Hassan M S, Beglinger C, Gyr N. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010; 10:208.
Rothermundt C, Omlin A, Gillessen S. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1144-6.
Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review. Gerontology 2009;.
Tan D S P, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye S B, Gore M E. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:5530-6.
Oberholzer C, Sawatzki M, Rothermundt C. [Weight loss and night sweats with unexpected tumor localization]. Praxis 2007; 96:1911-4.
Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M. Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. British journal of cancer 2006; 94:74-8.
Decker M, Rothermundt C, Holländer G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. The lancet oncology 2006; 7:693-4.
Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas O A, Jäger U, Fiegl M, Geissler K, Ludwig H, Huber H. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915-21.
Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jäger U, Heinz R. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer research 1995; 55:3854-9.
page 1 of 1